GP Labs plans production of cancer drugs in Russia

18 October 2017

The GP Laboratories, a supplier of UK licensed branded and generic pharmaceuticals, has announced its plans to establish a high-tech production of new drugs for the treatment of oncological and other diseases in Russia within the territory of the Moglino special economic zone in the Pskov region, according to recent statements of the press service of the regional administration reports.

The new plant is scheduled for commissioning in 2021. During the first stage of the project its range will include 10 drugs for the treatment of cancer, reports The Pharma Letter’s local correspondent.

The value of investments in the project is not disclosed, however, according to some sources close to the Pskov government, they may be in the range of $50-$70 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK